- Home
- MRM vs CNSP Comparison
MRM vs CNSP Comparison
Compare MRM & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRM | CNSP |
|---|---|---|
| Founded | 2000 | 2017 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6M | 8.5M |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | MRM | CNSP |
|---|---|---|
| Price | $0.34 | $5.35 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 15.2K | 2.2K |
| Earning Date | 10-23-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $32.01 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.53 | $1.90 |
| 52 Week High | $2.85 | $10.54 |
Technical Indicators
Market Signals| Indicator | MRM | CNSP |
|---|---|---|
| Relative Strength Index (RSI) | 13.35 | 50.16 |
| Support Level | N/A | $4.58 |
| Resistance Level | $1.31 | $5.52 |
| Average True Range (ATR) | 0.09 | 0.20 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 8.04 | 74.69 |
Price Performance
Historical ComparisonAbout MRM MEDIROM Healthcare Technologies Inc.
MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.